Press Releases Archives
2006
November 3, 2006:
iCo to Present at Rodman & Renshaw 8th Annual Healthcare Conference
Mr. John Meekison, iCo Therapeutics CFO, will present at the Rodman & Renshaw 8th Annual Healthcare Conference.
October 27, 2006:
iCo Therapeutics Welcomes Dr. David S. Boyer to Strategic Advisory Board
iCo Therapeutics Inc. announced today that Dr. David S. Boyer will join its strategic advisory team.
August 17, 2006:
iCo Therapeutics Appoints Chief Medical Officer
VANCOUVER, Canada – iCo Therapeutics Inc. announced today the appointment of Dr. Peter Hnik as Chief Medical Officer. Dr. Hnik is an ophthalmologist with a focus in glaucoma, neuro-ophthalmology, and deep industrial experience in retinal diseases such as age related macular degeneration and diabetic retinopathy.
June 28, 2006:
iCo Therapeutics Welcomes Dr. Jason Slakter to Strategic Advisory Board
iCo Therapeutics Inc. announced today that Dr. Jason Slakter will join its strategic advisory team. An internationally renowned retinal specialist, Dr. Slakter currently practices at the Vitreous-Retina-Macula Consultants in New York. He is a Clinical Pro.
June 20, 2006:
iCo Therapeutics to Present at EPIC in London, England
iCo Therapeutics Inc. announced today that Andrew Rae, iCo’s Chief Executive Officer, will present at EPIC, a European Partnering and Investment Conference taking place June 22nd at the Cumberland Hotel in London, England.
June 14, 2006:
iCo Therapeutics Recruits Leading Ophthalmologist to Strategic Advisory Board
iCo Therapeutics Inc. announced today that Dr. Philip Rosenfeld has joined iCo’s strategic advisory team. Dr. Rosenfeld is Professor of Ophthalmology at the world-renowned Bascom Palmer Eye Institute at the University of Miami, Miller School of Medicine.
June 5, 2006:
iCo Therapeutics Elects Dr. Richard W. Barker and William Jarosz as Independent Directors
iCo Therapeutics announced today the appointment of Dr. Richard W. Barker and William Jarosz to its board of directors.
April 19, 2006:
iCo Therapeutics to Present at Major Biotechnology Conference
iCo Therapeutics Inc. announced today that Andrew Rae, iCo’s Chief Executive Officer, will present at the Business Forum to be held in conjunction with the 2006 BIO International Annual Convention taking place April 9-12th at the McCormick Place Convention Center, Chicago, Illinois.
March 2, 2006:
World-Renowned Retinal Specialist joins iCo Therapeutics’ Strategic Advisory Team
iCo Therapeutics Inc. announced today that Dr. Alan Bird has joined iCo’s Strategic Advisory Team.
February 15, 2006:
iCo Therapeutics Selects Isis Pharmaceuticals to Manufacture and Supply iCo 007
iCo Therapeutics Inc. announced today that it has selected Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) to manufacture and supply iCo 007.
February 8, 2006:
Pace of iCo Unmatched by Biotech Competitors
2005
November 30, 2005:
iCo Therapeutics Announces Strategic Advisory Team
iCo Therapeutics Announces Strategic Advisory Team Dr. Julia Levy, Dr. George Lasezkay, Richard Glickman to provide strategic input to the Vancouver biotech firm.
November 15, 2005:
iCo Therapeutics to Present at BioFinance Early Phase 2005
iCo Therapeutics to Present at BioFinance Early Phase 2005 on November 16th, 2005
November 8, 2005:
iCo Therapeutics Named One of Canada’s Top Investment Prospects
iCo Therapeutics named one of Canada’s top investment prospects by the Ottawa Life Sciences Council
October 17, 2005:
iCo Therapeutics to Present at BIO InvestorForum in San Francisco
iCo Therapeutics to Present at BIO InvestorForum in San Francisco on October 20, 2005
September 29, 2005:
iCo Therapeutics to Present at BioContact
iCo Therapeutics Inc. announced today that Andrew Rae, iCo’s Chief Executive Officer, will present at the BioContact Quebec Biopharmaceutical Partnership Symposium to be held October 5-7th, 2005 in Quebec City, Quebec.
August 25, 2005:
Isis Pharmaceuticals Licenses Antisense Drug to iCo Therapeutics for the Treatment of Eye Diseases
Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) and iCo Therapeutics Inc. announced today that Isis has granted an exclusive worldwide license to iCo for the development and commercialization of ISIS 13650, a second-generation antisense drug.
July 19, 2005:
iCo Therapeutics Appoints Expert in Immunology and Ophthalmology as Chief Scientific Officer
iCo Therapeutics Inc. announced today the appointment of Professor Santa Jeremy Ono, a leading authority in the fields of immunology and ophthalmology, as Chief Scientific Officer.